Avecho, a Small-Cap ASX Biotech, Secures Partnership with Sandoz for CBD-Based Insomnia Solution

avecho, a small-cap asx biotech company, has partnered with sandoz to develop a groundbreaking cbd-based solution for insomnia. discover how this collaboration aims to innovate insomnia treatment and enhance patient outcomes.

Avecho Biotechnology Partners with Sandoz for CBD-Based Insomnia Treatment

Avecho Biotechnology Limited (ASX: AVE), a small-cap biopharmaceutical company based in Melbourne, Australia, has successfully established an exclusive licensing agreement with Sandoz Group AG to develop its cannabidiol (CBD) capsule aimed at treating insomnia. This partnership, which spans ten years, grants Sandoz exclusive commercial rights in Australia, while Avecho maintains rights in other regions. The deal includes an upfront payment of US$3 million, along with potential milestone payments of up to US$16 million. Avecho has recently received ethics approval to commence its pivotal Phase III clinical trial, representing the largest study of its kind in Australia, targeting the effectiveness of its TPM-enhanced CBD softgel capsule for insomnia. This development positions Avecho favorably within the growing CBD market.

  • The content on this website is intended for educational purposes only and should not be considered as medical or legal advice. CBD products are not designed to diagnose, treat, cure, or prevent any illness. This site also includes embedded content from platforms like YouTube and Instagram related to CBD, provided solely for informational purposes. We do not take responsibility for the accuracy or compliance of these external materials with local regulations.
user avatar

Ethan Carter

Hello! I’m Ethan, a 43-year-old content writer and CBD enthusiast. With a passion for crafting engaging content, I strive to educate and inspire others about the benefits of CBD. Join me on this journey to explore the world of cannabis and wellness!

Popular Posts

More Posts